DEA Moves to Schedule 7-Hydroxymitragynine as Schedule I

DEA's Temporary Scheduling of 7-Hydroxymitragynine

The Drug Enforcement Administration (DEA) has announced its intent to temporarily schedule 7-hydroxymitragynine as a Schedule I substance under the Controlled Substances Act. This decision, published in the Federal Register on July 6, 2026, will impose significant regulatory controls and sanctions on the handling of this compound. The move targets 7-hydroxymitragynine, including its isomers, esters, ethers, salts, and related compounds above a specified threshold.

Mechanism and Context of the Scheduling

The DEA's decision to schedule 7-hydroxymitragynine is primarily driven by concerns over its potential for abuse and lack of accepted medical use. Schedule I classification is reserved for substances considered to have a high potential for abuse and no accepted medical use in treatment in the United States. This temporary scheduling will last for up to two years, with the possibility of extension, during which the DEA will evaluate the compound's long-term scheduling status.

Implications for Policy and Research

The temporary scheduling of 7-hydroxymitragynine will have significant implications for research and policy. Researchers working with this compound will face increased regulatory hurdles, including the need for Schedule I research licenses, which are notoriously difficult to obtain. This could stifle ongoing and future research projects exploring the compound's potential therapeutic benefits. Additionally, the scheduling could impact the broader botanical and psychedelic markets, where 7-hydroxymitragynine is sometimes used in conjunction with other substances.

Risks and Unknowns

While the DEA's decision aims to mitigate potential misuse, it also introduces several risks and unknowns. The lack of access to 7-hydroxymitragynine for research purposes may hinder scientific understanding of its effects and potential benefits. Furthermore, the scheduling may drive the compound's market underground, complicating regulatory oversight and potentially increasing the risk of unregulated use. Stakeholders must weigh these risks against the DEA's concerns about abuse potential.

Looking Forward

Stakeholders in the psychedelic and botanical industries should prepare for potential disruptions resulting from this scheduling decision. Engaging in the public comment process could provide an avenue for influencing the DEA's final decision on the compound's long-term scheduling. Additionally, stakeholders may need to explore alternative compounds or adjust research and market strategies to adapt to the new regulatory landscape. The outcome of this temporary scheduling will likely set a precedent for how similar compounds are regulated in the future.